



COVID-19

Overview of Testing for SARS-CoV-2, the virus that causes COVID-19

Updated Feb. 11, 2022

Note: This document provides guidance on the different types of viral tests for SARS-CoV-2 available in the United States and their intended uses. It does not address issues regarding payment for or insurance coverage of such testing.

Summary of Recent Changes

Updates as of January 21, 2022



Revised to align with CDC's updated recommendations on [isolation and quarantine](#).

Revised to align with CDC recommendations for [people who are up to date with their vaccines](#).

[View Previous Updates](#)

Key Points

- People who have symptoms of COVID-19 or who have had known close contact to someone with COVID-19 should be tested for COVID-19.
- Point-of care serial screening testing can provide rapid results and is critical to identifying people with COVID-19 who do not have symptoms and slowing the spread of SARS-CoV-2. This is especially important when community risk or transmission levels are substantial or high.
- When selecting which SARS-CoV-2 test to use and interpreting results, healthcare providers, public health professionals, and those organizing and implementing testing should consider the context in which they are being used, including the prevalence of SARS-CoV-2 in the population being tested and the status (signs, symptoms, close contacts) of the person being tested.
- A person's vaccination status does not affect the results of their viral test for SARS-CoV-2.
- This guidance has been developed based on what is currently known about SARS-CoV-2 infection and COVID-19 and is subject to change as additional information becomes available.

A robust and responsive testing infrastructure is essential to the success of stopping the spread of SARS-CoV-2, the virus that causes COVID-19. This overview describes current information on the types of tests used to detect SARS-CoV-2 infection and their intended uses, including to diagnose infection, screening testing to reduce the virus's spread by people who do not have symptoms, and to monitor trends in infection. This guidance also includes considerations for:

- Health equity in testing
- Choosing a test

- Interpreting test results in vaccinated persons
- Testing in specific settings (e.g., K-12 schools, businesses, non-healthcare workplaces, correctional and detention facilities)
- Other considerations when deciding to test

This information is intended for use by healthcare providers, public health professionals, and those organizing and implementing testing in non-healthcare settings, such as schools, workplaces, and congregate housing. Information for the general public on SARS-CoV-2 testing is also [available](#).

Considerations When Testing

SARS-CoV-2 testing may be incorporated into a [comprehensive approach to reducing transmission](#) that also includes screening for [symptoms](#) and [contact tracing](#). When combined, these strategies can identify people infected with SARS-CoV-2 so that actions can be taken to slow and stop the spread of the virus.

People undergoing testing should [receive clear information](#) on

- The manufacturer and name of the test, the type of test, the purpose of the test, the performance specifications of the test, any limitations associated with the test, who will pay for the test, how the test will be performed, how and when people will receive test results, and;
- How to understand what the results mean, what actions need to happen after someone has negative or positive results, the difference between testing for workplace screening versus for medical diagnosis, who will receive the results, how the results may be used, and any consequences for declining to be tested.

Individuals tested are required to receive patient fact sheets as part of the test's [Emergency Use Authorization \(EUA\)](#).

Vaccination and SARS-CoV-2 Testing

If a person has received a COVID-19 vaccine, it does not affect the results of their SARS-CoV-2 viral tests (nucleic acid amplification tests [NAAT] or antigen). Because the Pfizer-BioNTech, Moderna, and Johnson & Johnson COVID-19 vaccines use the SARS-CoV-2 spike protein to generate an immune response, a positive serologic (antibody) test for spike protein IgM/IgG could indicate either previous infection or vaccination. Antibody testing is not currently recommended to assess for immunity to SARS-CoV-2 infection following COVID-19 vaccination or to assess the need for vaccination in an unvaccinated person. To evaluate for evidence of previous infection in a vaccinated individual, an antibody test specifically evaluating IgM/IgG to the nucleocapsid protein should be used (e.g., for public health surveillance or the diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C) or Multisystem Inflammatory Syndrome in Adults (MIS-A)). For guidance on quarantine and testing of [people who are up to date with their vaccines](#), please visit [COVID-19 Quarantine and Isolation | CDC](#).

Testing for SARS-CoV-2 Infection

Many types of tests are used to detect SARS-CoV-2,¹ and their performance characteristics vary.

- Some tests provide results rapidly (within minutes); others require time for processing.
- Some must be performed in a laboratory by trained personnel, some can be performed at the point of care, and others can be performed [at home](#) or anywhere.
- Some tests are very sensitive (i.e., few false-negative results or few missed detections of SARS-CoV-2); others are very specific (i.e., few false-positive results or few tests incorrectly identifying SARS-CoV-2 when the virus is not present); and some are both sensitive and specific.
- Some tests can be performed frequently because they are less expensive and easier to use than other tests, and supplies are readily available.

When selecting which SARS-CoV-2 test to use healthcare providers, public health professionals, and those organizing and implementing testing should consider the context in which they are being used, including the prevalence of SARS-CoV-2 in the population being tested (See Table 1) and the status (signs, symptoms, close contacts) of the person being tested.

Test Types

Viral tests, including Nucleic Acid Amplification Tests (NAATs, such as Reverse Transcription – Polymerase Chain Reaction) and antigen tests, are used as diagnostic tests to **detect current infection** with SARS-CoV-2 and to inform an individual's medical care. Viral tests can also be used as screening tests to reduce the transmission of SARS-CoV-2 by identifying infected persons who need to **isolate** from others. See FDA's list of [In Vitro Diagnostics Emergency Use Authorizations](#) for more information about the performance of specific authorized tests.

- **NAATs** are high-sensitivity, high-specificity tests for diagnosing SARS-CoV-2 infection. NAATs detect one or more viral ribonucleic acid (RNA) genes and indicate a current infection, or can indicate a recent infection due to prolonged viral RNA detection. NAAT results are not always direct evidence for the presence of virus capable of replicating or being transmitted to others. Most NAATs need to be performed in a laboratory, however some are point-of-care tests, and a few are self-tests. Time to results can vary by laboratory test (~1–3 days), but point-of-care or self-tests NAATs can produce results in about 15–60 minutes. Most NAATs produce qualitative results. NAATs can be performed on upper respiratory specimens, such as nasopharyngeal, nasal mid-turbinate, anterior nasal, or saliva.
- Antigen tests are immunoassays that detect the presence of a specific viral antigen. Antigen tests generally have similar specificity, but are less sensitive than most NAATs. Most are less expensive than NAATs and can provide results in minutes, making them useful in screening programs to quickly identify persons who are likely to have COVID-19. There are antigen tests available for at-home testing (self-testing), at the point of care, or in a laboratory. Because of the performance characteristics of antigen tests, it may be necessary to confirm some antigen test results (a negative test in persons with symptoms or a positive test in persons without symptoms) with a laboratory-based NAAT. Some point-of-care **NAATs** that provide presumptive results cannot be used for confirmatory testing. Use of the [Antigen Testing Algorithm](#) is recommended to determine when confirmatory testing is needed.

Correct interpretation of results from both antigen tests and confirmatory NAATs, when indicated, is important.

Positive test results allow for identification and isolation of infected persons, as well as a case interview to identify and notify the case's close contact(s) of exposure and the need to quarantine.

Negative test results in persons with known SARS-CoV-2 exposure suggest no current evidence of infection. These results represent a snapshot of the time around specimen collection and could change if the same test was performed again in one or more days. For guidance on quarantine after a negative test, visit [COVID-19 Quarantine and Isolation | CDC](#). In [healthcare facilities with an outbreak of SARS-CoV-2](#), recommendations for viral testing of healthcare providers, residents, and patients (regardless of their vaccination status) remain unchanged.

Negative test results in persons who have no symptoms and no known exposure suggest no infection. All persons being tested, regardless of their results, should talk to their healthcare provider about [risk reduction behaviors](#) that help prevent the transmission of SARS-CoV-2 (e.g., wearing a [well-fitting mask](#), physical distancing, avoiding crowds and poorly ventilated spaces).

Antibody (or serology) tests are used to **detect previous infection** with SARS-CoV-2 and can aid in the diagnosis of [multisystem inflammatory syndrome in children \(MIS-C\)](#) and in [adults \(MIS-A\)](#)². CDC does not recommend using antibody testing to diagnose current infection. Depending on the time when someone was infected and the timing of the test, the test might not detect antibodies in someone with a current infection. In addition, it is not currently known whether a positive antibody test result indicates immunity against SARS-CoV-2; therefore, at this time, antibody tests should not be used to determine if an individual is immune against reinfection. Antibody testing is being used for public health surveillance and epidemiologic purposes. Because antibody tests can have different targets on the virus, specific tests might be needed to assess for antibodies originating from past infection versus those from vaccination. For more information about COVID-19 vaccines and antibody test results, refer to [Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States](#).

Overview of Testing Scenarios

Diagnostic testing is intended to identify current infection in individuals and is performed when a person has signs or symptoms consistent with COVID-19, or is asymptomatic, but has recent known or suspected close contact exposure to SARS-CoV-2.

Examples of diagnostic testing include:

- Testing persons with symptoms consistent with COVID-19, whether or not they are up to date on their vaccinations.
- Testing persons as a result of contact tracing efforts.
- Testing persons who indicate that they had close contact exposure with someone suspected or confirmed as having COVID-19.

Screening tests are recommended for those who have no symptoms and no known, suspected, or reported close contact exposure to SARS-CoV-2. Screening helps to identify unknown cases so that measures can be taken to prevent further transmission.

Examples of screening include:

- Testing employees in a workplace setting
- Testing students, faculty, and staff in a school or university setting
- Testing a person before or after travel
- Testing at home for someone who does not have symptoms associated with COVID-19 and no known exposures to someone with COVID-19

Public health surveillance is intended to monitor population-level burden of disease, or to characterize the incidence and prevalence of disease. Surveillance testing is primarily used to gain information at a population level, rather than an individual level, and generally involves testing of de-identified specimens. Surveillance testing results are not reported back to the individual. As such, surveillance testing cannot be used for an individual's healthcare decision making or individual public health actions, such as isolation or quarantine.

An example of surveillance testing is [wastewater surveillance](#).

Choosing a Test

When choosing which test to use, it is important to understand the purpose of the testing (diagnostic or screening), performance of the test within the context of the level of community transmission, need for rapid results, and other considerations (See Table 1). For example, even a highly specific antigen test may have a poor positive predictive value (high number of false positives) when used in a community where prevalence of infection is low. As an additional example, use of a laboratory-based NAAT in a community with high transmission and increased test demand may result in diagnostic delays due to processing time and time to return results. Positive and negative predictive values of NAAT and antigen tests vary depending upon the pretest probability. Pretest probability considers both the prevalence of the level of community transmission as well as the clinical context of the individual being tested. Additional information is available on sensitivity, specificity, positive and negative predictive values for [antigen tests](#) and [antibody tests](#), and the relationship between [pretest probability and the likelihood of positive and negative predictive values](#)[458 KB, 1 Page]. Also see FDA's letters to clinical laboratory staff and healthcare providers on the potential for [false-positive results with antigen tests](#) and the potential for [false-negative results with molecular tests if a genetic variant of SARS-CoV-2 is found in the part of the viral genome assessed by the test](#).

Table 1 summarizes some characteristics of NAATs and antigen tests to consider for a testing program. Given the risk of transmission of SARS-CoV-2 from asymptomatic and presymptomatic persons with SARS-CoV-2 infection, use of antigen tests in asymptomatic and presymptomatic persons can be considered. FDA has provided a list of [FAQs for healthcare providers who are using diagnostic tests in screening asymptomatic individuals](#), and the Centers for Medicare & Medicaid Services will [temporarily exercise enforcement discretion](#) [↗](#) to enable the use of antigen tests that are not currently authorized for use in asymptomatic individuals for the duration of the COVID-19 public health emergency under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Laboratories that perform screening or diagnostic testing for SARS-CoV-2 must have a CLIA certificate and meet regulatory requirements. Tests that have received an EUA from FDA for point-of-care (POC) use can be performed with a CLIA certificate of waiver.

Table 1. NAAT and Antigen Test Differences to Consider When Planning for Diagnostic or Screening Use

	NAATs	Antigen Tests
Intended Use	Diagnose <i>current</i> infection	Diagnose <i>current</i> infection
Analyte Detected	Viral Ribonucleic Acid (RNA)	Viral Antigens
Specimen Type(s)	Nasal, Nasopharyngeal, Oropharyngeal, Sputum, Saliva	Nasal, Nasopharyngeal
Sensitivity	Varies by test, but generally high for laboratory-based tests and moderate-to-high for POC tests	Varies depending on the course of infection, but generally moderate-to-high at times of peak viral load*
Specificity	High	High
Test Complexity	Varies by test	Relatively easy to use
Authorized for Use at the Point-of-Care	Most are not, some are	Most are, some are not
Turnaround Time	Most 1-3 days. Some could be rapid in 15 minutes	Ranges from 15 minutes to 30 minutes
Cost/Test [^]	Moderate (~\$75-\$100/test)	Low (~\$5-\$50/test)
Advantages	<p>Most sensitive test method available</p> <p>Short turnaround time for NAAT POC tests, but few available</p> <p>Usually does not need to be repeated to confirm results</p>	<p>Short turnaround time (approximately 15 minutes)⁺</p> <p>When performed at or near POC, allows for rapid identification of infected people, thus preventing further virus transmission in the community, workplace, etc.</p> <p>Comparable performance to NAATs for diagnosis in symptomatic persons and/or if culturable virus present</p>
Disadvantages	<p>Longer turnaround time for lab-based tests (1–3 days)</p> <p>Higher cost per test</p> <p>A positive NAAT diagnostic test should not be repeated within 90 days, because people may continue to have detectable RNA after risk of transmission has passed</p>	<p>May need confirmatory testing</p> <p>Less sensitive (more false negative results) compared to NAATs, especially among asymptomatic people and with some variants</p>

*The decreased sensitivity of antigen tests might be offset if the POC antigen tests are repeated more frequently (i.e., serial testing at least weekly).

^ Costs for: [NAATs](#)

+Refers to point-of-care antigen tests only.

Health Equity in SARS-CoV-2 Testing

CDC's [COVID-19 Response Health Equity Strategy](#) outlines a plan to reduce the disproportionate burden of COVID-19 among racial and ethnic minority populations and other population groups (e.g., essential and frontline workers, people living in rural or frontier areas) who have experienced a disproportionate burden of COVID-19. One component to move towards greater health equity and to stop transmission of SARS-CoV-2 is ensuring availability of resources, including access to testing for populations who have experienced longstanding, systemic health and social inequities. All population groups, including racial and ethnic minority groups, should have equal access to affordable, quality and timely SARS-CoV-2 testing – with fast turnaround time for results — for diagnosis and screening to reduce community transmission. Efforts should be made to address barriers that might overtly or inadvertently create inequalities in testing.

In addition, completeness of race and ethnicity data is an important factor in understanding the impact the virus has on racial and ethnic minority populations. The U.S. Department of Health and Human Services has [required laboratories and testing facilities to report](#) race and ethnicity data to health departments, in addition to other data elements, for individuals tested for SARS-CoV-2 or diagnosed with COVID-19. Healthcare providers and public health professionals need to ask and record race and ethnicity for anyone receiving a reportable test result and ensure these data are reported with the person's test results in order to facilitate understanding the impact of COVID-19 on racial and ethnic minority populations.

In communities with a higher proportion of racial and ethnic minority populations and [other populations disproportionately affected](#) by COVID-19, health departments should ensure there is timely and equitable access to and availability of testing with fast result return, especially when the level of community transmission is substantial or high.

Some strategies to achieve this goal include:

- Use a [social vulnerability index](#) to assist in selecting testing sites.
- Assess the capacity of these sites to expand diagnostic and screening testing to meet the demand for impacted areas. This includes assessing the availability of free testing, wait times for testing and for results, and categories of available test (NAAT vs. antigen), as well as identifying and removing barriers to testing (e.g., alternatives to drive-through testing for a community where many do not have cars; availability of testing on evenings and weekends).
- Increase the availability of free testing sites in communities. Employers, community-based, and faith-based organizations can be important partners to increase the number of free, community-based testing sites. This expansion ensures that wait times both for testing and reporting of results are decreased, helping limit the spread of SARS-CoV-2.
- Increase public messaging about the importance of testing and communicate these messages in multiple languages and venues, particularly in communities at higher risk and disproportionately impacted by the virus.

Considerations for testing in different scenarios

Diagnostic testing

Testing persons with signs or symptoms consistent with COVID-19

Positive test results using a viral test (NAAT or antigen) in persons with signs or symptoms consistent with COVID-19 indicate that the person has COVID-19, independent of vaccination status of the person. A negative antigen test in persons with signs or symptoms of COVID-19 should be confirmed by NAAT, a more sensitive test. For more information, see the [Antigen Test Algorithm](#).

All persons (independent of vaccination status) with positive results should [isolate at home](#) or, if in a healthcare setting, be placed on [appropriate precautions](#). Most people with COVID-19 have mild illness and can recover at home without medical care. For more information, see CDC's [COVID-19 quarantine and isolation](#) guidance.

NAATs have detected SARS-CoV-2 RNA in some people's respiratory specimens long after they have recovered from COVID-19 (>3 months). [Studies](#) have not found evidence that clinically recovered adults with persistence of viral RNA have transmitted SARS-CoV-2 to others. These findings support the recommendation for a symptom-based, rather than test-based, strategy for ending isolation of most people, so that individuals who are no longer infectious are not kept unnecessarily isolated and excluded from work or other responsibilities.

Some adults with severe illness may produce replication-competent virus beyond 10 days that may warrant extending duration of isolation and precautions. A test-based strategy may be considered in consultation with infectious disease experts for persons with severe illness or who are severely immunocompromised. For more information, including on retesting persons previously infected with SARS-CoV-2, visit [Duration of Isolation and Precautions for Adults with COVID-19](#).

Testing asymptomatic persons who have had recent known or suspected close contact exposure to SARS-CoV-2

Identifying [close contacts](#) (people who have been within 6 feet for a combined total of 15 minutes or more during a 24-hour period) of persons with COVID-19 can help reduce the spread of SARS-CoV-2 in communities, workplaces, and schools when these close contacts quarantine themselves. Viral testing is recommended for individuals who are close contacts of persons with COVID-19. Regardless of their vaccination status, people who have had a close contact exposure with someone known or suspected of having COVID-19 should be tested at least 5 days after the incident, if possible, or earlier if symptoms develop. [Most people](#) with a history of test-confirmed COVID-19 who remain symptom-free after recovery do not need to retest or quarantine if another exposure occurs within 90 days after their initial infection. For more information, see CDC's [COVID-19 quarantine and isolation guidance](#).

Negative test results using a viral test (NAAT or antigen) in asymptomatic persons with recent known or suspected close contact exposure suggest no current evidence of infection. These results represent a snapshot of the time around specimen collection and could change if tested again in one or more days. In instances of higher pretest probability, such as high incidence of infection in the community, or a person with household or continuous contact to a person with COVID-19, clinical judgement should determine if a positive antigen result for an asymptomatic person should be followed by a laboratory-based confirmatory NAAT. Results from NAATs are considered the definitive result when there is a discrepancy between the antigen and NAAT test. For more information, see the [Antigen Test Algorithm](#).

Because of the potential for asymptomatic and presymptomatic transmission, it is important that individuals [exposed to people with known or suspected COVID-19](#) be quarantined (if they are not up to date with their vaccines) or wear a [well-fitting mask](#) in public settings (if they are [up to date with their vaccines](#) or if they had confirmed COVID-19 within the past 90 days). Regardless of their vaccination status, persons with positive results should follow CDC's guidance for isolation. Those not up to date with their vaccines with negative results should remain in [quarantine](#) [↗](#) for 5 days unless other guidance is given by the local, tribal, or territorial public health authority.

Based on local circumstances and resources, [CDC has provided options to shorten quarantine](#), including the use of a test-based strategy. More information on the scientific foundation behind these recommendations is available in [Options to Reduce Quarantine for Contacts of Persons with SARS-CoV-2 Infection Using Symptom Monitoring and Diagnostic Testing](#).

Confidentiality of the individual with COVID-19 should be maintained when informing close contacts of their possible exposure to SARS-CoV-2. People are encouraged to work with public health departments investigating cases of COVID-19, including identification of close contacts.

Information to help public health departments and healthcare providers prepare for expanded viral testing in facilities after known or suspected SARS-CoV-2 exposure or when there are substantial or high levels of community transmission (Table 2) is available in CDC's [Performing Broad-Based Testing for SARS-CoV-2 in Congregate Settings](#).

Testing to determine resolution of infection

[Accumulating evidence supports ending isolation and precautions](#) [↗](#) for persons with COVID-19 using a symptom-based strategy. Adults with more severe illness or who are immunocompromised may remain infectious up to 20 days or longer after symptom onset, so a test-based strategy could be considered in consultation with infectious disease experts for these people. For all others, a test-based strategy is no longer recommended except to discontinue isolation or precautions earlier than would occur under the symptom-based strategy.

People with immunocompromising conditions or people who take immunosuppressive medications or therapies are at increased risk for severe COVID-19. Immunocompromised people ages 5 years and older should receive a primary COVID-19 vaccine series as soon as possible. In addition, [moderately or severely immunocompromised people](#) may not mount a protective immune response after initial vaccination, and their protection by primary vaccination may wane over time. Therefore, ACIP and CDC have made [age-specific recommendations](#) for an additional primary dose and a booster dose for this population including, but not limited to, people receiving chemotherapy for cancer, people with hematologic cancers such as chronic lymphocytic leukemia, people receiving stem cell or organ transplants, people receiving hemodialysis, and [people using certain medications](#) that might blunt the immune response to vaccination.

People who are immunocompromised should talk to a healthcare provider about the potential for reduced immune responses to COVID-19 vaccines and the need to continue to follow current prevention measures (including wearing a [well-fitting mask](#), [staying 6 feet apart from others](#) they don't live with, using self-tests, and avoiding crowds and poorly ventilated indoor spaces) to protect themselves against COVID-19 until advised otherwise by their healthcare provider. [Close contacts](#) of immunocompromised people should also stay up to date with their COVID-19 vaccinations to help protect these people.

Screening Testing

Testing asymptomatic persons without recent known or suspected exposure to SARS-CoV-2 for early identification, isolation, and disease prevention

Unvaccinated persons with asymptomatic or presymptomatic infection are frequent contributors to community SARS-CoV-2 transmission and occurrence of COVID-19 illness. Serial testing of unvaccinated persons, regardless of their signs or symptoms, is a key component to a layered approach to preventing the transmission of SARS-CoV-2. Screening allows early identification and isolation of persons who are asymptomatic, presymptomatic, or have only mild symptoms and who might be unknowingly transmitting virus. Screening testing may be most valuable in areas with substantial or high community transmission levels (Table 2), in areas with low vaccination coverage, and in certain settings (see examples below).

Use of POC tests, such as antigen tests, for screening can play an important role in testing as a prevention strategy due to the short turn-around time for results. Antigen tests are most sensitive in the early stages of infection when viral loads are high and have decreasing sensitivity as disease progresses and when transmission may be less likely. The decreased sensitivity of antigen tests might be offset if the POC antigen tests are repeated more frequently (i.e., serial testing at least weekly). Thus, when screening large numbers of persons (e.g., a well-defined cohort) without known or suspected exposure to SARS-CoV-2, test sensitivity may be less critical than whether the test can be performed more frequently and provide rapid results with immediate isolation of infected individuals.³ Outbreak prevention and control are increasingly thought to depend largely on the frequency of testing and the speed of reporting (an advantage of antigen tests) and is only marginally improved – in the context of serial tests — by the higher test sensitivity of NAATs. In screening settings where antigen tests are used on asymptomatic people, laboratory-based confirmatory NAAT testing may be needed for certain individuals who test positive. For interpretation of screening test results, please see the [Antigen Test Algorithms](#).

People without symptoms and without known exposure to COVID-19 do not need to quarantine while awaiting screening test results. If a person tests positive on a screening test and is referred for a confirmatory test, they should quarantine until they receive the results of their confirmatory test. For guidance on quarantine and testing of [people who are up to date with their vaccines](#), please visit [COVID-19 Quarantine and Isolation | CDC](#) .

Screening testing as a prevention strategy

- Screening testing can improve detection of SARS-CoV-2.
 - Serial testing (within cohorts) with rapid isolation of infected individuals may facilitate re-opening of businesses, communities, and schools (in-person instruction in K-12 schools⁴) with less risk of a surge in local cases.
 - Frequent testing (1–2 times per week) combined with other risk reduction strategies, contributed to low case rates in university settings.⁵
- Frequency of testing could be informed by:
 - Current level of community transmission (Table 2), in addition to other known factors about the epidemiology of transmission in a particular cohort. If community transmission is substantial or high (Table 2), more frequent screening might be needed regardless of other indicators.

- Characteristics (e.g., size, proximity of people, duration of interaction) of the school, workplace, residential setting, or gathering.
- The [incubation period for COVID-19](#). Given that the incubation period can be up to 14 days, CDC recommends conducting screening testing at least weekly.
- Testing using a tiered approach, analogous to testing described in [high-density critical workplace](#) and [institutes of higher education](#) guidance, could be considered and might be particularly important for low incidence areas.
 - On some school campuses (e.g., institutes of higher learning), unvaccinated students may be tested upon arrival on campus or upon return from extended breaks.
- See additional guidance to facilitate implementation of [screening in congregate settings](#).

Examples of groups to prioritize for screening testing

These examples can guide development of local recommendations to prioritize **people not up to date with their vaccines** for screening testing, taking into account feasibility and costs. Initial sampling of subgroups for screening testing to evaluate the need for additional screening testing in a particular group may also be considered. In communities with substantial or high levels of community transmission (Table 2), health departments should ensure resources (trained staff and testing supplies) are available to provide expanded screening testing. **These examples are not listed in a priority order.**

Racial and ethnic minority groups and other [populations disproportionately affected](#) by COVID-19

Teachers and staff in [K-12 schools](#) and/or childcare settings

Students, faculty, and staff at [institutions of higher education](#) (including community colleges and technical schools)

Workers in [high-density worksites](#) or worksites with large numbers of [close contact](#) to co-workers or customers (restaurant workers, transportation workers, grocery store workers)

Government workers with public interactions as part of their duties (post office workers)

First responders (police, fire, emergency medical technician [EMT]) and [healthcare personnel](#)

Residents and staff in [congregate settings](#), such as shelters serving the [homeless](#) and [correctional and detention facilities](#) or residential settings, such as [nursing homes](#) or those serving persons with disabilities; workplaces that provide congregate housing (fishing vessels, offshore platforms, farmworker housing or wildland firefighter camps); and military facilities (barracks)

Persons who recently traveled, either [domestically](#) or [internationally](#)

Persons who attended [large gatherings](#)

[Patients in healthcare settings](#)

Specific age groups (e.g., young adults) for whom increases in COVID19 have been documented early as incidence rises, especially in communities with substantial or high transmission (Table 2).

Table 2. Level of Community Transmission

Indicator	Low	Moderate	Substantial	High
-----------	-----	----------	-------------	------

Indicator	Low	Moderate	Substantial	High
Cumulative number of new cases per 100,000 persons within the last 7 days*	<10	10-49	50-99	≥100
Percentage of NAATs that are positive during the last 7 days†	<5%	5%-7.9%	8%-9.9%	≥10.0%

Indicators should be calculated for counties or core based statistical areas, although in rural areas with low population density, multiple jurisdictions might need to be combined to make the indicators more useful for decision-making. The indicators listed can be found by county on CDC's [COVID Data Tracker Website under "county view"](#).

* Number of new cases in the county (or other administrative level) in the last 7 days divided by the population in the county (or other administrative level) and multiplying by 100,000.

† Number of positive tests in the county (or other administrative level) during the last 7 days divided by the total number of tests resulted in the county (or other administrative level) during the last 7 days. [Calculating Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-2\) Laboratory Test Percent Positivity: CDC Methods and Considerations for Comparisons and Interpretation](#).

Public Health Surveillance Testing for SARS-CoV-2

Public health surveillance is the ongoing, systematic collection, analysis, and interpretation of health-related data essential to the planning, implementation, and evaluation of public health practice. See CDC's [Introduction to Public Health Surveillance](#).

Public health surveillance testing is intended to monitor community- or population-level outbreaks of disease or to characterize the incidence and prevalence of disease. Surveillance testing is performed on de-identified specimens, and, thus, results are not linked to individual people. Public health surveillance testing results cannot be used for individual decision-making.

Public health surveillance testing may sample a certain percentage of a specific population to monitor for increasing or decreasing prevalence or to determine the population effect from community interventions, such as social distancing. An example of public health surveillance testing is when a state public health department develops a plan to randomly select and sample a percentage of all people in a city on a rolling basis to assess local infection rates and trends.

"Wastewater," also referred to as "sewage," includes water from household/building use (i.e., toilets, showers, sinks) that can contain human fecal waste, as well as water from non-household sources (e.g., rainwater and industrial use), can be tested for RNA from SARS-CoV-2. Data from wastewater testing are not meant to replace existing COVID-19 surveillance systems. Institutes of higher education with the resources to implement wastewater surveillance should develop a wastewater surveillance strategy in consultation with local public health authorities.

CDC is working with state, local, territorial, academic, and commercial partners to conduct surveillance to better understand COVID-19 in the United States and recently conducted a [multistate assessment of SARS-CoV-2 seroprevalence in blood donors](#).

- [Cases, Data, and Surveillance](#)
 - [COVID-19-Associated Hospitalization Surveillance Network \(COVID-NET\)](#)
 - [COVID-19 Serology Surveillance](#)
 - [National Wastewater Surveillance System \(NWSS\)](#)
 - [FAQ: COVID-19 Data & Surveillance](#)
- [Surveillance and Data Analytics](#)
- [CDC's Diagnostic Multiple Assay for Flu and COVID-19 at Public Health Laboratories and Supplies](#)
- [Emerging SARS-CoV-2 Variants \(SARS-CoV-2 Strain Surveillance\)](#)

Setting-specific Testing Guidance

Testing in Healthcare Settings

[Nursing Homes](#)

[Acute Care Facilities](#)

[Infection Prevention and Control Recommendations for Healthcare Personnel](#)

Testing in Communities, Schools and Workplaces

[K-12 Schools](#)

[Institutes of Higher Education](#)

[Healthcare Personnel](#)

[Non-Healthcare Workplaces](#)

[High-Density Critical Workplaces](#)

[Homeless Shelters](#)

[Correctional and Detention Facilities](#)

Testing Information for the Public

[Testing Guidance for the Public](#)

[Testing and International Air Travel](#)

[Frequently Asked Questions: Testing](#)

Other Testing Resources

[Antigen Testing Algorithm](#)

[Interim Guidelines for COVID-19 Antibody Testing](#)

[Pooled Procedures for Testing](#)

[Laboratory Resources](#)

[Performing Facility-Wide Testing in Nursing Homes](#)

[Testing in K-12 Settings Playbook](#) [↗](#)

[Antigen Testing for Screening in Non-Healthcare Workplaces](#)

Previous Updates

Updates from Previous Content [^](#)

As of October 22, 2021

- Based on evolving evidence, CDC recommends fully vaccinated people get tested 5-7 days after close contact with a person with suspected or confirmed COVID-19.

As of August 2, 2021

- Revised to align with CDC recommendations for fully vaccinated individuals

As of July 1, 2021

- Revised to align with CDC recommendations for fully vaccinated individuals

As of June 14, 2021

- Expansion on the description of categories of tests, choosing a test, and addition of intended uses of testing
- Addition of health equity considerations related to testing, including discussion on ensuring equitable testing access and availability

- Discussion on expanded availability to, and use of, screening tests to reduce asymptomatic spread
- Discussion on testing of vaccinated individuals and interpretation of test results
- Inclusion of links to setting-specific testing guidance

As of September 18, 2020

- Due to the significance of asymptomatic and pre-symptomatic transmission, this guidance further reinforces the need to test asymptomatic persons, including [close contacts](#) of a person with documented SARS-CoV-2 infection.

As of August 24, 2020

- Diagnostic testing categories have been edited to focus on testing considerations and actions to be taken by individuals undergoing testing

As of July 17, 2020

- Except for rare situations, a test-based strategy is no longer recommended to determine when an individual with a SARS-CoV-2 infection is no longer infectious (i.e., to discontinue Transmission-Based Precautions or home isolation)

As of July 2, 2020

- Added screening to possible testing types
- Removed examples – please refer to setting specific guidance

References

1. Mina MJ, Andersen KG. COVID testing: One size does not fit all. *Science* 2021;371(6525):126-127. doi: [10.1126/science.abe9187](https://doi.org/10.1126/science.abe9187) [↗](#) .
2. Morris SB, Schwartz NG, Patel P, et al. Case series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection – United Kingdom and United States, March – August 2020. *MMWR*. 2020;69(40):1450-1456. doi: [10.15585/mmwr.mm6940e1](https://doi.org/10.15585/mmwr.mm6940e1) [↗](#) .
3. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States. *JAMA Netw Open*. 2020;3(7):e2016818.
4. Larremore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. *Sci Adv*. 2020;20(7):eabd5393. doi:[10.1126/sciadv.abd5393](https://doi.org/10.1126/sciadv.abd5393) [↗](#) .
5. Bracis C, Burns E, Moore M, Swan D, Reeves DB, Schiffer JT, Dimitrov D. Widespread testing, case isolation and contact tracing may allow safe school reopening with continued moderate physical distancing: A modeling analysis of King County, WA data. *Infect Dis Model*. 2020;13(6):24-3 doi: [10.1016/j.idm.2020.11.003](https://doi.org/10.1016/j.idm.2020.11.003) [↗](#) .

Last Updated Feb. 11, 2022